Market Overview

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

Share:

ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

PR Newswire

HOUSTON and VANCOUVER, March 28, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ((TSX-V: EPI, NASDAQ:EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on March 28, 2018 in Vancouver, British Columbia, Canada (the "Meeting").

ESSA Pharma Inc (CNW Group/ESSA Pharma Inc)

At the Meeting, the shareholders of the Company (the "Shareholders") set the number of directors at eight and re-elected board members David R. Parkinson, Richard M. Glickman, Marianne Sadar, Raymond Andersen, Gary Sollis, Franklin M. Berger, Scott Requadt and Hugo Beekman to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

David R. Parkinson

68,461,278

99.74%

179,319

0.26%

Richard M. Glickman

68,410,188

99.66%

230,409

0.34%

Marianne Sadar

68,463,378

99.74%

177,219

0.26%

Raymond Andersen

68,461,278

99.74%

179,319

0.26%

Gary Sollis

68,583,278

99.92%

57,319

0.08%

Franklin M. Berger

68,513,278

99.81%

127,319

0.19%

Scott Requadt

68,501,278

99.80%

139,319

0.20%

Hugo Beekman

68,501,278

99.80%

139,319

0.20%

 

At the Meeting, the Shareholders also re-appointed Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company by show of hands.

Further, the Shareholders, by ordinary resolution passed by ballot vote, ratified, confirmed and approved the Company's stock option plan, which was previously approved by the board of directors of the Company (the "Board") on February 21, 2018. Detailed results of the voting in respect of the stock option plan are as follows:

Votes by Ballot

Votes For

% Votes For

Votes Against

% Votes Against

By all shareholders

61,180,225

89.13%

7,460,372

10.87%

 

The Shareholders, by ordinary resolution passed by ballot vote, also ratified, confirmed and approved the re-grant, repricing and extension of the expiry dates of certain of the outstanding stock options of the Company granted to certain directors, officers, employees and consultants, as further described in the management information circular dated February 23, 2018 in connection with the Meeting (the "Circular"). Detailed results of the voting in respect of the re-grant, repricing and extension of expiry dates of stock options are as follows:

Votes by Ballot

Votes For

% Votes For

Votes Against

% Votes Against

By all shareholders

61,150,175

89.09%

7,490,422

10.91%

By disinterested shareholders

17,151,379

69.60%

7,490,422

30.40%

 

At the Meeting, the Shareholders, by ordinary resolution passed by ballot vote, also ratified, confirmed and approved the grant of an aggregate of 14,523,000 stock options to certain directors, officers, employees and consultants, as further described in the Circular. Detailed results of the voting in respect of the stock option grants are as follows:

Votes by Ballot

Votes For

% Votes For

Votes Against

% Votes Against

By all shareholders

61,149,600

89.09%

7,490,997

10.91%

By disinterested shareholders

17,150,804

69.60%

7,490,997

30.40%

 

Further, the Shareholders, by special resolution passed by ballot vote, approved the consolidation of the Company's common shares on a basis of up to 20 pre-consolidation common shares being consolidated into one post-consolidation common share, or such lesser number of pre-consolidation common shares as may be accepted by the TSX Venture Exchange ("TSX-V") and approved by the Board. Pursuant to the resolution passed by the Shareholders, the Board is authorized, at any time in its absolute discretion, to determine whether or not to proceed with the consolidation without further approval, ratification or confirmation of the Shareholders. Further details regarding the consolidation are set out in the Circular. Detailed results of the voting in respect of the common share consolidation are as follows:

Votes by Ballot

Votes For

% Votes For

Votes Against

% Votes Against

By all shareholders

68,577,197

99.91%

63,400

0.09%

 

At the Meeting, the Shareholders, by ordinary resolution passed by ballot vote, also ratified, confirmed and approved the Company's restricted share unit plan, which was previously approved by Board on February 21, 2018. Detailed results of the voting in respect of the restricted share unit plan are as follows:

Votes by Ballot

Votes For

% Votes For

Votes Against

% Votes Against

By all shareholders

61,179,700

89.13%

7,460,897

10.87%

By disinterested shareholders

17,180,904

69.72%

7,460,897

30.28%

 

About ESSA Pharma I

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com